Literature DB >> 9324361

Mechanism underlying counterregulation of autoimmune diabetes by IL-4.

R Mueller1, L M Bradley, T Krahl, N Sarvetnick.   

Abstract

Diabetes in nonobese diabetic (NOD) mice is an autoimmune disease characterized by the destruction of the beta cells in the pancreas. We have previously reported that transgenic expression of interleukin-4 (IL-4) counterregulates the disease process, completely protecting NOD mice from insulitis and diabetes. Here we demonstrate the presence of autoreactivity but lack of pathogenicity of the IL-4-regulated lymphocytes. The importance of T cell diversity for the protective effect of IL-4 is demonstrated through breeding with transgenic BDC2.5 mice, which have an almost exclusively monoclonal T cell repertoire. Limitation of T cell diversity abrogated the protection by IL-4. We suggest that "immune deviation" in NOD-IL-4 mice is mediated by the pancreatic tissue itself, which causes activation of distinct, nonpathogenic T cell specificities.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9324361     DOI: 10.1016/s1074-7613(00)80362-3

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  21 in total

Review 1.  Regulation of development and function of memory CD4 subsets.

Authors:  L M Bradley; J Harbertson; G C Freschi; R Kondrack; P J Linton
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

2.  CCR4-bearing T cells participate in autoimmune diabetes.

Authors:  Soon H Kim; Mary M Cleary; Howard S Fox; David Chantry; Nora Sarvetnick
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

Review 3.  Achieving antigen-specific immune regulation.

Authors:  Kevan C Herold
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

Review 4.  Regulatory T cells and type 1 diabetes.

Authors:  Brygida C Bisikirska; Kevan C Herold
Journal:  Curr Diab Rep       Date:  2005-04       Impact factor: 4.810

5.  Treatment of autoimmune diabetes recurrence in non-obese diabetic mice by mouse interferon-beta in combination with an analogue of 1alpha,25-dihydroxyvitamin-D3.

Authors:  C Gysemans; E Van Etten; L Overbergh; A Verstuyf; M Waer; R Bouillon; C Mathieu
Journal:  Clin Exp Immunol       Date:  2002-05       Impact factor: 4.330

6.  Germ line deletion of the CD1 locus exacerbates diabetes in the NOD mouse.

Authors:  F D Shi; M Flodstrom; B Balasa; S H Kim; K Van Gunst; J L Strominger; S B Wilson; N Sarvetnick
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-05       Impact factor: 11.205

7.  Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice.

Authors:  David Bending; Hugo De la Peña; Marc Veldhoen; Jenny M Phillips; Catherine Uyttenhove; Brigitta Stockinger; Anne Cooke
Journal:  J Clin Invest       Date:  2009-02-02       Impact factor: 14.808

Review 8.  Regulation of type 1 diabetes, tuberculosis, and asthma by parasites.

Authors:  Zhugong Liu; Qian Liu; David Bleich; Padmini Salgame; William C Gause
Journal:  J Mol Med (Berl)       Date:  2009-10-21       Impact factor: 4.599

9.  Helminth infection can reduce insulitis and type 1 diabetes through CD25- and IL-10-independent mechanisms.

Authors:  Qian Liu; Krishnan Sundar; Pankaj K Mishra; Gity Mousavi; Zhugong Liu; Andrew Gaydo; Farhang Alem; David Lagunoff; David Bleich; William C Gause
Journal:  Infect Immun       Date:  2009-09-14       Impact factor: 3.441

10.  Tissue-targeted therapy of autoimmune diabetes using dendritic cells transduced to express IL-4 in NOD mice.

Authors:  Rémi J Creusot; Shahriar S Yaghoubi; Keiichi Kodama; Demi N Dang; Vu H Dang; Karine Breckpot; Kris Thielemans; Sanjiv S Gambhir; C Garrison Fathman
Journal:  Clin Immunol       Date:  2008-03-12       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.